31 research outputs found
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma
Full text link
Combined modality treatment and adjuvant lumbo-splenic radiotherapy (RT) in supra-diaphragmatic (SD) clinical stage (CS) I-II Hodgkin disease (HD) results in decreased rates of infra-diaphragmatic (ID) nodal relapses (R)
No full textLong term results of the GELA study, R-CHOP vs. CHOP in elderly patients with diffuse large B-cell lymphoma.
No full textFront-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS
No full textFront-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS
No full textMulticenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients.
No full textVECP-Bleo regimen as treatment of advanced stage aggressive non-Hodgkin’s Lymphoma in elderly patients a GOELAMS protocol
No full textOverall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
No full text
